Study identifier:4522IL/0008
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Randomised, Parallel-Group Dose-Response Study with the HMG-CoA Reductase Inhibitor ZD4522 and Atorvastatin in Subjects with Primary Hypercholesterolaemia
dyslipidaemia
Phase 3
-
-
-
-
Interventional
-
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|